Griesinger F, Curigliano G, Thomas M, Subbiah V, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol 2022 Aug 13. pii: S0923-7534(22)03866.
PMID: 35973665